- Data demonstrates mortality reduction in endotoxemic patients through
use of combined diagnostic and therapeutic -
TORONTO, March 18 /CNW/ - Spectral Diagnostics Inc. (TSX:SDI) today
announced that new findings were presented showing a mortality reduction in
endotoxemic patients through the combined use of Spectral's EAA(TM) Endotoxin
Activity Assay, the only FDA cleared diagnostic for the measurement of
endotoxin, and Toray Medical Company's Toraymyxin(TM) column, a blood
purification device that absorbs endotoxin from the bloodstream. The findings
will be presented in a symposium entitled "Measuring and targeting endotoxin
in critical illness - from theory to practice" at the 28th International
Symposium on Intensive Care and Emergency Medicine. The conference takes place
in Brussels, Belgium from March 18-21, 2008 and focuses on developments in
research, therapy, and management of critically ill patients.
"Our unique EAA(TM) diagnostic offers critical care physicians valuable
information on the diagnosis of endotoxemia. Used in combination with
Toray's therapy, EAA(TM) provides actionable data that has the potential to
lead to a reduction in mortality as demonstrated by the findings presented at
this important conference," said Dr. Paul Walker, President and CEO of
Spectral Diagnostics. "Toraymyxin(TM) is highly effective in removing
endotoxin from the bloodstream and our EAA(TM) product has the ability to
identify patients who could benefit from the therapy and monitor its results.
Together, the combined diagnostic and therapeutic has the potential to provide
a more effective treatment for patients with endotoxemia."
Data compiled using Spectral's EAA(TM) will also be featured in several
posters being presented at the conference. A manuscript describing the study
of the combined use of EAA(TM) and Toraymyxin(TM) is currently being written
and will be submitted for publication in 2008.
About Spectral Diagnostics
Spectral is a developer of innovative technologies for comprehensive
disease management. Spectral's lead product is its EAA(TM) Endotoxin Activity
Assay, the only FDA approved diagnostic for the measurement of endotoxin.
Spectral technologies provide accurate and timely information to clinicians
enabling the early initiation of appropriate and targeted therapy. Spectral is
listed on TSX under the symbol SDI.
Information in this news release that is not current or historical
factual information may constitute forward-looking information within the
meaning of securities laws. Implicit in this information, particularly in
respect of the future outlook of Spectral and anticipated events or results,
are assumptions based on beliefs of Spectral's senior management as well as
information currently available to it. While these assumptions were considered
reasonable by Spectral at the time of preparation, they may prove to be
incorrect. Readers are cautioned that actual results are subject to a number
of risks and uncertainties, including the availability of funds and resources
to pursue R&D projects, the successful and timely completion of clinical
studies, the ability of Spectral to take advantage of business opportunities
in the biomedical industry, the granting of necessary approvals by regulatory
authorities as well as general economic, market and business conditions, and
could differ materially from what is currently expected.
The TSX has not reviewed and does not accept responsibility for the
adequacy or accuracy of this statement.
For further information:
For further information: Dr. Paul Walker, President & CEO, (416)
626-3233 ex. 2100; James Smith, Investor Relations, (416) 815-0700 ext. 229,